Does the media refer more to XNCR or RCKT?

In the previous week, Rocket Pharmaceuticals had 3 more articles in the media than Xencor. MarketBeat recorded 13 mentions for Rocket Pharmaceuticals and 10 mentions for Xencor. Xencor's average media sentiment score of 0.41 beat Rocket Pharmaceuticals' score of 0.38 indicating that Xencor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 2 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rocket Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor VIR or RCKT?

In the previous week, Vir Biotechnology had 8 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 21 mentions for Vir Biotechnology and 13 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 0.38 beat Vir Biotechnology's score of -0.12 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rocket Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, AVBP or RCKT?

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ArriVent BioPharma N/A N/A -$166.31M -$3.47 N/A Rocket Pharmaceuticals N/A N/A -$223.12M -$0.17 N/A

Is AVBP or RCKT more profitable?

ArriVent BioPharma's return on equity of -52.47% beat Rocket Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets ArriVent BioPharma N/A -52.47% -48.68% Rocket Pharmaceuticals N/A -57.19% -48.18%

Does the media refer more to AVBP or RCKT?

In the previous week, Rocket Pharmaceuticals had 1 more articles in the media than ArriVent BioPharma. MarketBeat recorded 13 mentions for Rocket Pharmaceuticals and 12 mentions for ArriVent BioPharma. Rocket Pharmaceuticals' average media sentiment score of 0.38 beat ArriVent BioPharma's score of 0.24 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 2 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Rocket Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, ORIC or RCKT?

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oric Pharmaceuticals N/A N/A -$129.47M -$1.35 N/A Rocket Pharmaceuticals N/A N/A -$223.12M -$0.17 N/A

Is ORIC or RCKT more profitable?

Oric Pharmaceuticals' return on equity of -35.35% beat Rocket Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Oric Pharmaceuticals N/A -35.35% -33.39% Rocket Pharmaceuticals N/A -57.19% -48.18%

Does the media favor ORIC or RCKT?

In the previous week, Oric Pharmaceuticals had 5 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 18 mentions for Oric Pharmaceuticals and 13 mentions for Rocket Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 0.59 beat Rocket Pharmaceuticals' score of 0.38 indicating that Oric Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rocket Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RCKT or ABSI?

In the previous week, Absci had 2 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 15 mentions for Absci and 13 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 0.38 beat Absci's score of -0.11 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Absci 0 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Rocket Pharmaceuticals (RCKT) Competitors

$3.30 -0.04 (-1.05%)

As of 11:21 AM Eastern

Compare

RCKT vs. XNCR, VIR, AVBP, ORIC, and ABSI

Should you buy Rocket Pharmaceuticals stock or one of its competitors? Rocket Pharmaceuticals's main competitors and comparable companies include Xencor (XNCR), Vir Biotechnology (VIR), ArriVent BioPharma (AVBP), Oric Pharmaceuticals (ORIC), and Absci (ABSI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rocket Pharmaceuticals compare to Xencor?

Xencor (NASDAQ:XNCR) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Xencor has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

Rocket Pharmaceuticals has a net margin of 0.00% compared to Xencor's net margin of -155.59%. Xencor's return on equity of -28.66% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-155.59%	-28.66%	-20.38%
Rocket Pharmaceuticals	N/A	-57.19%	-48.18%

Xencor has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	13.45	-$91.92M	-$2.17	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A

Xencor currently has a consensus price target of $24.86, indicating a potential upside of 9.43%. Rocket Pharmaceuticals has a consensus price target of $8.57, indicating a potential upside of 159.35%. Given Rocket Pharmaceuticals' higher possible upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30

98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 5.1% of Xencor shares are owned by company insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Rocket Pharmaceuticals had 3 more articles in the media than Xencor. MarketBeat recorded 13 mentions for Rocket Pharmaceuticals and 10 mentions for Xencor. Xencor's average media sentiment score of 0.41 beat Rocket Pharmaceuticals' score of 0.38 indicating that Xencor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	2 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rocket Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Xencor beats Rocket Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Vir Biotechnology?

Vir Biotechnology (NASDAQ:VIR) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

Rocket Pharmaceuticals has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -29.99% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-29.99%	-23.62%
Rocket Pharmaceuticals	N/A	-57.19%	-48.18%

Rocket Pharmaceuticals has lower revenue, but higher earnings than Vir Biotechnology. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56M	22.24	-$437.99M	-$1.86	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A

65.3% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 2.9% of Vir Biotechnology shares are owned by company insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Vir Biotechnology had 8 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 21 mentions for Vir Biotechnology and 13 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 0.38 beat Vir Biotechnology's score of -0.12 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rocket Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vir Biotechnology presently has a consensus price target of $20.63, indicating a potential upside of 128.91%. Rocket Pharmaceuticals has a consensus price target of $8.57, indicating a potential upside of 159.35%. Given Rocket Pharmaceuticals' higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Vir Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30

Vir Biotechnology has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market.

Summary

Vir Biotechnology beats Rocket Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to ArriVent BioPharma?

ArriVent BioPharma (NASDAQ:AVBP) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 8.6% of ArriVent BioPharma shares are owned by company insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

ArriVent BioPharma has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market.

ArriVent BioPharma's return on equity of -52.47% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-52.47%	-48.68%
Rocket Pharmaceuticals	N/A	-57.19%	-48.18%

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A

ArriVent BioPharma currently has a consensus price target of $44.43, suggesting a potential upside of 48.60%. Rocket Pharmaceuticals has a consensus price target of $8.57, suggesting a potential upside of 159.35%. Given Rocket Pharmaceuticals' higher probable upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30

In the previous week, Rocket Pharmaceuticals had 1 more articles in the media than ArriVent BioPharma. MarketBeat recorded 13 mentions for Rocket Pharmaceuticals and 12 mentions for ArriVent BioPharma. Rocket Pharmaceuticals' average media sentiment score of 0.38 beat ArriVent BioPharma's score of 0.24 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Rocket Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Rocket Pharmaceuticals beats ArriVent BioPharma on 8 of the 14 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

Oric Pharmaceuticals' return on equity of -35.35% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.35%	-33.39%
Rocket Pharmaceuticals	N/A	-57.19%	-48.18%

Oric Pharmaceuticals currently has a consensus target price of $19.45, indicating a potential upside of 42.63%. Rocket Pharmaceuticals has a consensus target price of $8.57, indicating a potential upside of 159.35%. Given Rocket Pharmaceuticals' higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30

In the previous week, Oric Pharmaceuticals had 5 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 18 mentions for Oric Pharmaceuticals and 13 mentions for Rocket Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 0.59 beat Rocket Pharmaceuticals' score of 0.38 indicating that Oric Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rocket Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oric Pharmaceuticals has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market.

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A

Summary

Oric Pharmaceuticals beats Rocket Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Absci?

Rocket Pharmaceuticals (NASDAQ:RCKT) and Absci (NASDAQ:ABSI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

98.4% of Rocket Pharmaceuticals shares are held by institutional investors. Comparatively, 52.1% of Absci shares are held by institutional investors. 21.3% of Rocket Pharmaceuticals shares are held by insiders. Comparatively, 10.5% of Absci shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Rocket Pharmaceuticals has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. Rocket Pharmaceuticals' return on equity of -57.19% beat Absci's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-57.19%	-48.18%
Absci	-7,756.38%	-66.21%	-57.63%

Rocket Pharmaceuticals currently has a consensus target price of $8.57, suggesting a potential upside of 159.35%. Absci has a consensus target price of $13.43, suggesting a potential upside of 48.53%. Given Rocket Pharmaceuticals' higher probable upside, equities analysts clearly believe Rocket Pharmaceuticals is more favorable than Absci.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30
Absci	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Rocket Pharmaceuticals has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, Absci has a beta of 2.35, indicating that its share price is 135% more volatile than the broader market.

Absci has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A
Absci	$2.80M	554.12	-$115.18M	-$0.83	N/A

In the previous week, Absci had 2 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 15 mentions for Absci and 13 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 0.38 beat Absci's score of -0.11 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Absci	0 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Rocket Pharmaceuticals beats Absci on 9 of the 16 factors compared between the two stocks.

Get Rocket Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RCKT vs. The Competition

Export

Metric	Rocket Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$362.82M	$3.69B	$6.97B	$13.06B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-19.44	10.36	269.56	25.27
Price / Sales	N/A	1,288.04	596.64	100.41
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	1.29	17.39	13.00	6.30
Net Income	-$223.12M	-$13.32M	$3.45B	$347.83M
7 Day Performance	-8.45%	0.34%	0.57%	0.94%
1 Month Performance	-9.20%	0.13%	1.22%	0.90%
1 Year Performance	9.08%	53.78%	66.67%	20.40%

Rocket Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RCKT Rocket Pharmaceuticals	2.4082 of 5 stars	$3.31 -1.0%	$8.57 +159.3%	+8.1%	$362.82M	N/A	N/A	240	News Coverage Earnings Report Analyst Forecast Insider Trade
XNCR Xencor	1.4979 of 5 stars	$21.58 +3.7%	$24.86 +15.2%	+197.8%	$1.55B	$125.58M	N/A	280
VIR Vir Biotechnology	2.0047 of 5 stars	$8.89 +0.8%	$20.63 +132.0%	+96.9%	$1.49B	$68.56M	N/A	580	Analyst Revision
AVBP ArriVent BioPharma	2.3664 of 5 stars	$30.99 +0.5%	$44.83 +44.7%	+66.5%	$1.44B	N/A	N/A	40	News Coverage Positive News Earnings Report Analyst Forecast
ORIC Oric Pharmaceuticals	2.3645 of 5 stars	$13.62 +0.9%	$19.45 +42.8%	+39.6%	$1.40B	N/A	N/A	80	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RCKT) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rocket Pharmaceuticals (RCKT) Competitors

RCKT vs. XNCR, VIR, AVBP, ORIC, and ABSI

How does Rocket Pharmaceuticals compare to Xencor?

Summary

How does Rocket Pharmaceuticals compare to Vir Biotechnology?

Summary

How does Rocket Pharmaceuticals compare to ArriVent BioPharma?

Summary

How does Rocket Pharmaceuticals compare to Oric Pharmaceuticals?

Summary

How does Rocket Pharmaceuticals compare to Absci?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT vs. The Competition

Rocket Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rocket Pharmaceuticals (RCKT) Competitors

RCKT vs. XNCR, VIR, AVBP, ORIC, and ABSI

How does Rocket Pharmaceuticals compare to Xencor?

Which has more volatility and risk, XNCR or RCKT?

Is XNCR or RCKT more profitable?

Which has preferable earnings & valuation, XNCR or RCKT?

Do analysts rate XNCR or RCKT?

Do insiders & institutionals have more ownership in XNCR or RCKT?

Does the media refer more to XNCR or RCKT?

Summary

How does Rocket Pharmaceuticals compare to Vir Biotechnology?

Is VIR or RCKT more profitable?

Which has stronger valuation & earnings, VIR or RCKT?

Do institutionals & insiders believe in VIR or RCKT?

Does the media favor VIR or RCKT?

Do analysts rate VIR or RCKT?

Which has more risk and volatility, VIR or RCKT?

Summary

How does Rocket Pharmaceuticals compare to ArriVent BioPharma?

Do institutionals and insiders hold more shares of AVBP or RCKT?

Which has more risk and volatility, AVBP or RCKT?

Is AVBP or RCKT more profitable?

Which has higher valuation and earnings, AVBP or RCKT?

Do analysts prefer AVBP or RCKT?

Does the media refer more to AVBP or RCKT?

Summary

How does Rocket Pharmaceuticals compare to Oric Pharmaceuticals?

Is ORIC or RCKT more profitable?

Do analysts prefer ORIC or RCKT?

Does the media favor ORIC or RCKT?

Which has more risk & volatility, ORIC or RCKT?

Do insiders & institutionals believe in ORIC or RCKT?

Which has higher earnings and valuation, ORIC or RCKT?

Summary

How does Rocket Pharmaceuticals compare to Absci?

Do insiders and institutionals hold more shares of RCKT or ABSI?

Is RCKT or ABSI more profitable?

Do analysts prefer RCKT or ABSI?

Which has more risk and volatility, RCKT or ABSI?

Which has higher valuation and earnings, RCKT or ABSI?

Does the media refer more to RCKT or ABSI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT vs. The Competition

Rocket Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools